Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Shuwaikh, Kuwait.
Emergency Psychiatry Department, Kuwait Centre for Mental Health (KCMH), Shuwaikh, Kuwait.
Am J Ther. 2019 Jan/Feb;26(1):e96-e102. doi: 10.1097/MJT.0000000000000535.
Lamotrigine (LAM), an antiepileptic, with panoply of indications and uses in neurology, is FDA approved, in psychiatry, for bipolar prophylaxis. Apart from this indication, trend of its use in psychiatry is on the rise addressing a multitude of disorders.
LAM remains one of only few psychotropic drugs with antiglutamate activity. This might render LAM a potential therapeutic option in treatment-resistant major psychiatric disorders. We reviewed LAM pharmacology and its diverse indications while examining the extant evidence.
EMBASE, Ovid MEDLINE, PubMed, Scopus, Web of Science, and Cochrane Database of Systemic Reviews were searched for all relevant studies up to date of June 2016.
Sound evidence supports use of LAM for acute bipolar depression and prophylaxis, treatment-resistant schizophrenia, treatment-resistant obsessive-compulsive disorder, posttraumatic stress disorder, depersonalization disorder, and affective dysregulation and behavioral dyscontrol domains of borderline personality disorder. Less compelling evidence is present for use in behavioral and psychological symptoms of dementia and neuropsychiatric sequelae of traumatic brain injury. No evidence supports use in autism spectrum disorder or acute unipolar depression.
LAM is an important addition to the psychopharmacological armamentarium. Level of evidence supporting the use of LAM in off-label indications is highly variable, and hence, sound clinical judgment is necessary for its proper use and placement in real-life psychiatric practice and psychopharmacotherapy algorithms.
拉莫三嗪(LAM)是一种抗癫痫药,在神经病学中有多种适应症和用途,已获得美国食品和药物管理局(FDA)批准,可用于预防双相情感障碍。除了这一适应症外,LAM 在精神病学中的使用趋势也呈上升趋势,可用于治疗多种疾病。
LAM 是唯一具有抗谷氨酸活性的精神药物之一。这可能使 LAM 成为治疗难治性主要精神疾病的潜在治疗选择。我们审查了 LAM 的药理学及其多种适应症,同时检查了现有证据。
EMBASE、Ovid MEDLINE、PubMed、Scopus、Web of Science 和 Cochrane 系统评价数据库均检索了截至 2016 年 6 月的所有相关研究。
有充分证据支持将 LAM 用于治疗急性双相抑郁和预防、治疗抵抗性精神分裂症、治疗抵抗性强迫症、创伤后应激障碍、人格解体障碍以及边缘性人格障碍的情感调节和行为控制障碍领域。对于痴呆的行为和心理症状以及创伤性脑损伤的神经精神后遗症的治疗效果证据不充分。没有证据支持将 LAM 用于自闭症谱系障碍或急性单相抑郁。
LAM 是精神药理学武器库中的重要补充。支持 LAM 在非适应证中的使用的证据水平差异很大,因此,需要有良好的临床判断,以正确使用 LAM,并将其放置在现实中的精神病学实践和精神药理学治疗算法中。